Objective: To evaluate the therapeutic efficacy of injecting highly agglutinative staphylococcin (HASL) and cisplatin into pericardial cavity of lung cancer patients with pericardial effusion. Methods: 81 patients wer...Objective: To evaluate the therapeutic efficacy of injecting highly agglutinative staphylococcin (HASL) and cisplatin into pericardial cavity of lung cancer patients with pericardial effusion. Methods: 81 patients were randomized into two groups: 45 in the experimental group (HASL and Cisplatin) and 36 in the control group (Cisplatin). At first pericardial effusion was drained out from a intrapericardial catheter and then different drugs were infused, respectively. 24 h after perfusion the draining continued again until drainage quantity was less than 30 mL every day. The draining lasted 10–15 days. Results: The response rate was 91.1% for the experimental group and 80.6% for the control group. There was no significant difference between the two groups (P>0.05). The complete remission was 77.8% for the experimental group and 52.8% for the control group, which was statistically significant difference (P<0.05). The adverse effects were myelosuppression and nausea and vomiting, which were 35.6% and 40.0% in the experimental group and 72.2% and 66.7% in the control group, respectively (P<0.01, P<0.05). Conclusion: Inject- ing HASL and cisplatin into pericardial cavity may be a better way to control pericardial effusion of lung cancer.展开更多
文摘Objective: To evaluate the therapeutic efficacy of injecting highly agglutinative staphylococcin (HASL) and cisplatin into pericardial cavity of lung cancer patients with pericardial effusion. Methods: 81 patients were randomized into two groups: 45 in the experimental group (HASL and Cisplatin) and 36 in the control group (Cisplatin). At first pericardial effusion was drained out from a intrapericardial catheter and then different drugs were infused, respectively. 24 h after perfusion the draining continued again until drainage quantity was less than 30 mL every day. The draining lasted 10–15 days. Results: The response rate was 91.1% for the experimental group and 80.6% for the control group. There was no significant difference between the two groups (P>0.05). The complete remission was 77.8% for the experimental group and 52.8% for the control group, which was statistically significant difference (P<0.05). The adverse effects were myelosuppression and nausea and vomiting, which were 35.6% and 40.0% in the experimental group and 72.2% and 66.7% in the control group, respectively (P<0.01, P<0.05). Conclusion: Inject- ing HASL and cisplatin into pericardial cavity may be a better way to control pericardial effusion of lung cancer.
